Table 1

Clinicopathologic features of the patient population

CharacteristicAll patients n=304 (%)
Corticosteroid exposureP value*
Prednisone 0 to <10 mg n=226 (%)Prednisone >10 mg prior to ICI n=14 (%)Prednisone >10 mg during ICI n=64 (%)
Gender0.68
 Male235 (77)172 (76)11 (79)52 (82)
 Female69 (23)54 (24)3 (21)12 (18)
Cirrhosis0.23
 Present216 (71)156 (69)9 (64)51 (80)
 Absent87 (29)69 (31)5 (36)13 (20)
 Unknown1 (0.3)1 (0.4)0 (0)0 (0)
Etiology of chronic liver disease0.85
 Viral196 (65)144 (64)10 (71)42 (66)
 Non-viral106 (34)80 (35)4 (29)22 (34)
 Unknown2 (0.7)2 (0.9)0 (0)0 (0)
Child-Turcotte-Pugh Class0.6
 A225 (74)170 (75)9 (64)46 (72)
 B79 (26)56 (25)5 (36)18 (28)
Barcelona Clinic Liver Cancer stage0.35
 A–B74 (24)51 (23)3 (21)20 (31)
 C230 (76)175 (77)11 (79)44 (69)
Maximum diameter of largest lesion (cm)0.96
 Median (IQR)5.5 (5.5)5.5 (6)5 (-)5 (4.5)
 n202166135
Metastatic sites0.81
 0–1166 (55)136 (60)1 (7)29 (76)
 >245 (15)36 (16)0 (0)9 (9)
 Unknown93 (31)54 (24)13 (93)26 (41)
Prior systemic therapy for HCC0.66
 0–1277 (81)204 (90)13 (93)60 (94)
 >227 (9)21 (10)1 (7)4 (6)
Immunotherapy treatment0.1
 Monotherapy279 (92)204 (82)14 (100)61 (91)
 Combination25 (8)22 (18)0 (0)3 (9)
ECOG Performance Status0.46
 0–1197 (65)162 (72)1 (7)34 (53)
 ≥213 (4)9 (4)0 (0)4 (6)
 Unknown94 (31)55 (24)13 (93)26 (41)
Alfa-fetoprotein0.42
 <400 ng/mL178 (59)129 (57)10 (71)39 (61)
 >400 ng/mL118 (39)93 (41)4 (29)21 (33)
 Unknown8 (3)4 (2)0 (0)4 (6)
Albumin0.25
 Median (IQR)36 (9)36 (8)33 (10)36 (10)
 n2982201464
Bilirubin0.64
 Median (IQR)14 (12)14 (12)14.5 (12)15 (10)
 n3022241464
Platelet count0.58
 Median (IQR)160 (119)160 (120)100 (–)162 (92)
 n210171138
  • *Excludes the “Unknown” category in the statistical test.

  • ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitors.